Filing Details

Accession Number:
0001181431-14-008853
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-02-24 17:53:07
Reporting Period:
2014-02-20
Filing Date:
2014-02-24
Accepted Time:
2014-02-24 17:53:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1369786 Sagent Pharmaceuticals Inc. SGNT Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1518010 Michael Logerfo C/O Sagent Pharmaceuticals, Inc.
1901 North Roselle Road, Suite 700
Schaumburg IL 60195
Chief Legal Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-02-20 4,638 $22.05 19,957 No 4 S Direct
Common Stock Acquisiton 2014-02-20 20,000 $4.23 39,957 No 4 M Direct
Common Stock Disposition 2014-02-20 3,894 $21.78 36,063 No 4 S Direct
Common Stock Disposition 2014-02-21 590 $21.84 35,473 No 4 F Direct
Common Stock Disposition 2014-02-22 441 $21.75 35,032 No 4 F Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 F Direct
No 4 F Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option to Buy Disposition 2014-02-20 20,000 $0.00 20,000 $4.23
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2018-08-15 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,000 Indirect See Footnote
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.75 to $22.01, inclusive.
  2. Shares held by a member of Mr. Logerfo's immediate family sharing the same household. Mr. Logerfo disclaims beneficial ownership of such shares.
  3. Stock option granted on August 15, 2008 and vests 25% per year over four years.